Human intravenous immunoglobulin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer's disease - sprookjes - yvandenbroek - TriplyDB

Human intravenous immunoglobulin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer's disease

Human intravenous immunoglobulin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer's disease

http://www.wikidata.org/entity/Q34419295

about

Herpes Simplex Virus Type 1 and Other Pathogens are Key Causative Factors in Sporadic Alzheimer's Disease New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs Intravenous immunoglobulin and Alzheimer's disease: what now?'Clinical trials in Alzheimer's disease': immunotherapy approaches A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease.A human monoclonal IgG that binds aβ assemblies and diverse amyloids exhibits anti-amyloid activities in vitro and in vivo.Human anti-Aβ IgGs target conformational epitopes on synthetic dimer assemblies and the AD brain-derived peptide.Intravenous immunglobulin binds beta amyloid and modifies its aggregation, neurotoxicity and microglial phagocytosis in vitro.Granulocyte colony stimulating factor attenuates inflammation in a mouse model of amyotrophic lateral sclerosis.Production of monocytic cells from bone marrow stem cells: therapeutic usage in Alzheimer's disease.Beta-amyloid auto-antibodies are reduced in Alzheimer's disease.Animal models in the drug discovery pipeline for Alzheimer's disease Protective effect of 14-3-3 antibodies on stressed neuroretinal cells via the mitochondrial apoptosis pathway IgG Conformer's Binding to Amyloidogenic Aggregates.An N-terminal antibody promotes the transformation of amyloid fibrils into oligomers and enhances the neurotoxicity of amyloid-beta: the dust-raising effect.Effects of human intravenous immunoglobulin on amyloid pathology and neuroinflammation in a mouse model of Alzheimer's disease.Impact of intravenous immunoglobulin on the dopaminergic system and immune response in the acute MPTP mouse model of Parkinson's disease Mechanisms of action of naturally occurring antibodies against β-amyloid on microglia.Effective anti-Alzheimer Aβ therapy involves depletion of specific Aβ oligomer subtypes.Increased levels of antigen-bound β-amyloid autoantibodies in serum and cerebrospinal fluid of Alzheimer's disease patients.Intracranial injection of Gammagard, a human IVIg, modulates the inflammatory response of the brain and lowers Aβ in APP/PS1 mice along a different time course than anti-Aβ antibodies.Brain bioavailability of human intravenous immunoglobulin and its transport through the murine blood-brain barrier.Aβ and Inflammatory Stimulus Activate Diverse Signaling Pathways in Monocytic Cells: Implications in Retaining Phagocytosis in Aβ-Laden Environment Intravenous immunoglobulin protects neurons against amyloid beta-peptide toxicity and ischemic stroke by attenuating multiple cell death pathways.Disease-modifying effect of intravenous immunoglobulin in an experimental model of epilepsy.Susceptibility to focal and global brain ischemia of Alzheimer mice displaying aβ deposits: effect of immunoglobulin Amyloid-β plaque reduction, endogenous antibody delivery and glial activation by brain-targeted, transcranial focused ultrasound.Utilization of APPswe/PS1dE9 Transgenic Mice in Research of Alzheimer's Disease: Focus on Gene Therapy and Cell-Based Therapy Applications.Targeting Beta amyloid: a clinical review of immunotherapeutic approaches in Alzheimer's disease.Pathogenic and physiological autoantibodies in the central nervous system.A review: treatment of Alzheimer's disease discovered in repurposed agents.Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies.Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward.Neuroinflammation in Alzheimer's disease: from pathogenesis to a therapeutic target.Immunomodulation and AD--down but not out.Should development of Alzheimer's disease-specific intravenous immunoglobulin be considered?Aβ-Immunotherapeutic strategies: a wide range of approaches for Alzheimer's disease treatment.Huperzine A alleviates synaptic deficits and modulates amyloidogenic and nonamyloidogenic pathways in APPswe/PS1dE9 transgenic mice.Development of antihuman IgG antibodies and hematologic deficits but not clinical abnormalities in C57BL/6 mice after repeated administration of human intravenous immunoglobulin.Immunological evidence and regulatory potential for cell-penetrating antibodies in intravenous immunoglobulin.

P2860

Q26781578-1A4EE830-69BE-4F74-A4BE-E24A12F4151D Q26866006-13E30A0F-12D9-45C1-BEAF-FCE3FD24E359 Q27000371-7B66E8E0-1024-4062-B5A7-00E59F6CA1E2 Q27008979-9BEC8913-8E6C-4E1A-A8BB-69FC41B3EFFF Q34376103-E8AE8380-BBFD-4C85-8A1A-CA9B43C12C5D Q34473306-C9A3AE2A-44B1-454D-87D5-90ADD5C3DAAE Q34500145-554A8415-B7E3-4A27-BCBE-28054573D417 Q34733689-69BFB28E-E2E4-4CAD-9D6D-2664A9866460 Q35137333-1C73EFCD-B775-4C91-A394-2C006CA5E4C6 Q35195013-64ACB874-F438-4A62-AE52-764C262ECFA7 Q35541293-73928349-90FD-431F-8943-DDC961604E54 Q35589962-5851C2C1-0987-45F8-96D4-4964B03EADA3 Q35676010-B0B5F99C-2CF5-4569-9B7A-746FC532DCC9 Q35772596-225C05A9-5024-48DD-A3B2-7906B7F63D65 Q36002121-6AD76F44-AAEB-4759-9BAD-C98D33D14B17 Q36156604-9725690C-E354-4CD2-974C-467F45319D62 Q36462680-5DEB8B40-4B9C-4361-95F3-A6626D7A06FD Q36689356-B75013FF-C810-4BA0-AADF-74DC959719F4 Q36894417-17EB54BA-D7D2-4003-B1EF-E858423D2AB1 Q37024947-2F1F03AA-CC25-4EBE-8ED3-91D598433F86 Q37340312-844F749D-E69A-49AE-A00C-37C05E1C9C9A Q37365658-C34A4A09-68C4-4359-8845-F5E18E56BFE2 Q37471244-CCA2420A-F8B2-4C30-86FB-787BB1293144 Q37487547-820E2258-1429-45AA-ACB1-C1583D92B9E3 Q37578846-01067969-5CFB-476E-8357-BC016AAA5861 Q37665371-1BA20282-1E31-404A-8B94-D913DC9446DD Q37725032-1A87004A-1593-4246-9F53-2875609681BF Q37960498-9BE76239-01CF-4FDE-9FE7-56332FFD3E3C Q37980146-96EA3860-643B-4D5B-B865-06605322F753 Q38020957-440BDC89-F564-4D9C-9909-5FE0C1E17504 Q38073138-5AFF5122-9C2B-45E7-99CC-D7959F2698C5 Q38079317-55DF51B1-010C-4D20-9C05-94CD21C4E3B2 Q38184618-20AA57ED-4396-4FDC-BF2B-7BBF36D417A1 Q38202910-797F4330-68C4-4830-9E78-20567B058598 Q38208226-DBF5E9DB-0445-43DF-AD3A-4C88A8209570 Q38283308-31DCE582-40D4-40DD-99DD-FA5A9972B06C Q38881198-7E90EEBB-BA93-4BB3-8ED6-1ED2751C0806 Q39457273-8DA38401-287E-48F3-8F4D-8A4B910C477D Q40986104-0F02FDD9-FF03-4EF3-9FE2-43CFAF7D40E2 Q41038467-59336988-72A2-4CA7-A32D-F9A03832D619

P2860

Human intravenous immunoglobulin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer's disease

http://www.wikidata.org/entity/Q34419295

description

2010 nî lūn-bûn

@nan

2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Human intravenous immunoglobul ...... e model of Alzheimer's disease

@ast

Human intravenous immunoglobul ...... e model of Alzheimer's disease

@en

Human intravenous immunoglobul ...... e model of Alzheimer's disease

@nl

type

label

Human intravenous immunoglobul ...... e model of Alzheimer's disease

@ast

Human intravenous immunoglobul ...... e model of Alzheimer's disease

@en

Human intravenous immunoglobul ...... e model of Alzheimer's disease

@nl

prefLabel

Human intravenous immunoglobul ...... e model of Alzheimer's disease

@ast

Human intravenous immunoglobul ...... e model of Alzheimer's disease

@en

Human intravenous immunoglobul ...... e model of Alzheimer's disease

@nl

P1433

Q34419295-7E4527C0-2AEE-4AF0-A61A-2A731507B37E

P1476

Q34419295-A1E9168D-C8EA-42A1-9629-DB8C27C52BDE

P2093

Q34419295-1808D6A9-73F4-4F3B-8121-FB996A6321B7

Q34419295-3CCA2E06-6452-454A-B5A7-14F4A9A95906

Q34419295-4CE96D7A-FAAA-47C7-A0ED-78695AFD0DD3

Q34419295-517B6EF8-5F1C-47C3-8058-3CA45A519A64

Q34419295-6237EBC1-41E7-4753-9DEF-3C8A838F0353

Q34419295-730DC0FD-22BC-41D2-93FE-98965AA31D67

Q34419295-76DEB3E4-A762-4F61-8551-3EB44403A15B

Q34419295-AF599E46-B331-4885-AAC3-4101DEB6A470

Q34419295-AFDB7882-75D8-4601-89B2-F15979DE697F

Q34419295-D4D770D3-0328-4436-A376-2C9B80090FD8

P2860

Q34419295-01B0AAE4-3838-4039-A2C5-4A938240DDB7

Q34419295-10CF2F76-A33F-4CF9-8048-5E5BF312799C

Q34419295-11206472-D278-42B4-86A4-98D664479D84

Q34419295-11F58F27-D8E1-49C0-A172-B7EAD6A35D82

Q34419295-155B9A85-27D9-422F-A377-7D42DDEEAA2E

Q34419295-1C0D59A0-3F47-4E98-8DA5-5B21AD66FB8D

Q34419295-1F472D3F-1AF8-41AC-8C64-3B296ABA48D8

Q34419295-1F776150-9121-4F33-BDF3-33685D964F8A

Q34419295-2193C832-79F2-40F1-84BE-27B3D2DB83D1

Q34419295-271B7BC7-9ABA-4442-982D-BB79735DAAD2

P2888

Q34419295-6C28E9FE-BE12-40AB-BAD9-B93FF43C2BBB

P304

Q34419295-5CC18AC3-DBB6-45AA-BE7C-A503A39836E1

P31

Q34419295-9F528D46-5FBF-4B38-9632-B0AE4F019E6E

P356

Q34419295-C7F4A140-7353-4F08-A726-56B7BA3124CA

P478

Q34419295-8874E648-A9EA-4ED8-8027-9A70F50FFF75

P577

Q34419295-0E9572DA-A5A7-4D59-9964-0BBBA22CA912

P5875

Q34419295-285F50B4-E553-4043-901F-0B6CB9EA7703

P6179

Q34419295-D1E2B6B2-FDC2-43EF-BF67-882B249BA1B3

P698

Q34419295-20766260-7293-468D-A66C-7F9CDDE48961

P921

Q34419295-CC4AC8DC-0102-4588-8D79-A48528816DC0

P932

Q34419295-D98A32F6-98A3-4D96-BEB6-DF6392E213DD

P356

P1433

Journal of Neuroinflammation

P1476

Human intravenous immunoglobul ...... e model of Alzheimer's disease

@en

P2093

Gundars Goldsteins

http://www.w3.org/2001/XMLSchema#string

Heikki Tanila

http://www.w3.org/2001/XMLSchema#string

Jari Koistinaho

http://www.w3.org/2001/XMLSchema#string

Jens Grosche

http://www.w3.org/2001/XMLSchema#string

Johanna Magga

http://www.w3.org/2001/XMLSchema#string

Katja Kanninen

http://www.w3.org/2001/XMLSchema#string

Lakshman Puli

http://www.w3.org/2001/XMLSchema#string

Milla Koistinaho

http://www.w3.org/2001/XMLSchema#string

Rea Pihlaja

http://www.w3.org/2001/XMLSchema#string

Suvi Neulamaa

http://www.w3.org/2001/XMLSchema#string

P2860

Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo

Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo

Alzheimer's disease: genes, proteins, and therapy

Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase

Anti-inflammatory actions of intravenous immunoglobulin

Optimized survival of hippocampal neurons in B27-supplemented Neurobasal, a new serum-free medium combination

Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease.

A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease.

P2888

P304

90

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1742-2094-7-90

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2010-12-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49664915

http://www.w3.org/2001/XMLSchema#string

P6179

1044541142

http://www.w3.org/2001/XMLSchema#string

P698

21138577

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

3004875

http://www.w3.org/2001/XMLSchema#string